Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of CHS-1701 vs Neulasta in Healthy Subjects
NCT02418104Phase 1Completed
- Sponsor
- Coherus BioSciences, Inc.
- Start
- May 2015
- Primary completion
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pegfilgrastim in neutropenia (2 arms), sponsored by Coherus BioSciences, Inc. Primary endpoint: Immunogenicity (Anti-Drug Antibodies) at 84 days. Started May 2015; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02418104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02418104.